🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Out now in NEJM Evidence evidence.nejm.org/doi/full/10.10… A Randomized Trial of an App-Based Therapeutic for Lower Urinary Tract Symptoms. NEJM Evidence European Urology Uniklinik Freiburg Stacy Loeb, MD Kari Tikkinen Dean Elterman Laura Bukavina Axel S. Merseburger

Conservative approaches, including education and lifestyle changes, are under-utilized in the treatment of male lower urinary tract symptoms (LUTS). Gratzke and colleagues report the results of an RCT testing an app-based educational program for LUTS. eviden.cc/4imNXsH

In a recent interview, Christian Gratzke, MD, (Christian Gratzke) explained why an app shows promise for patients with lower urinary tract symptoms. Read through his insights here: urologytimes.com/view/app-shows…

Fundació Puigvert Barcelona Iván Schwartzmann European Association of Urology (EAU) Eur Urol Focus Nice study by Iván Schwartzmann Jean-Nicolas Cornu and colleagues. Moving towards more options for men including HoLEP and MISTs. Featured in recent issue of Eur Urol Focus Christian Gratzke

Opevesostat trial in #mCRPC Christian Gratzke Uniklinik Freiburg joins Zach Klaassen Georgia Cancer Center Christian Gratzke discusses the Phase III trial of opevesostat, a CYP11A1 inhibitor, for mCRPC. Targeting androgen biosynthesis upstream, this novel approach aims for deeper testosterone

Follow us on Telegram for the latest updates from the European Urology family of journals — European Urology, European Urology Focus, European Urology Oncology, and European Urology Open Science. Be the first to read new articles, editorials, special issues, and key

“This randomized trial demonstrated significant symptom improvement measured by the [International Prostate Symptom Score] for patients with [lower urinary tract symptoms] using app-based therapeutics compared with usual care.” Full trial results: eviden.cc/4imNXsH

Digital therapeutics for LUTS: A randomized trial of app-based treatment. Christian Gratzke Uniklinik Freiburg & Laura Wiemer, MD Kranus Health GmbH join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss an app-based randomized trial for treating lower urinary tract symptoms. This digital therapeutic delivers

🎖️Trainees in oncology and across all fields of medicine! Do not miss this manuscript on how to effectively respond to reviewer comments! Thanks Andrew Vickers Rod Dunn Christian Gratzke Morgan Roupret Alberto Briganti et al. European Urology Eur Urol Focus European Urology Oncology 🙏 OncoAlert

Original Article: “A Randomized Trial of an App-Based Therapeutic for Lower Urinary Tract Symptoms” by Christian Gratzke and colleagues eviden.cc/4imNXsH Markus Grabbert #ClinicalTrials #Urology

🆕article in press: Pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide and androgen deprivation therapy for mHSPC: the randomized, double-blind, phase III KEYNOTE-991 study Christian Gratzke doi.org/10.1016/j.anno…

KEYNOTE-991: Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT in treatment-naive mHSPC. ⛔ Did not improve rPFS ⛔ No OS benefit ⛔ More toxicity Christian Gratzke Mehmet Ali Nahit Sendur Annals of Oncology OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos annalsofoncology.org/article/S0923-…

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study annalsofoncology.org/article/S0923-… The phase III

Had a blast co editing this special issue of Eur Urol Focus with my uber-brilliant, bug 🧫loving mentor and friend @scientistatlrge We discuss 💡 idea of treating bugs like drugs and connections to all things GU

Opevesostat trial in #mCRPC Christian Gratzke Uniklinik Freiburg joins Zach Klaassen Georgia Cancer Center Christian Gratzke discusses the Phase III trial of opevesostat, a CYP11A1 inhibitor, for mCRPC. Targeting androgen biosynthesis upstream, this novel approach aims for deeper testosterone

Digital therapeutics for LUTS: A randomized trial of app-based treatment. Christian Gratzke Uniklinik Freiburg & Laura Wiemer, MD Kranus Health GmbH join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss an app-based randomized trial for treating lower urinary tract symptoms. This digital therapeutic delivers

We are extremely proud to announce that our 2024 IF is 5.6. We would like to sincerely thank all Authors, Reviewers, Readers, and Editorial Team! #impactfactor #UroSoMe #MedTwitter

Do patients regret to receive a testicular prosthesis after orchiectomy?🥚🥚 👇Check out the article from Luca Boeri M.D. et al. on this topic👇 eu-focus.europeanurology.com/article/S2405-…

Midyear Update on Next-Generation Antiandrogens in Prostate Cancer x.com/i/broadcasts/1…

🩸💥 Many have asked: “Where did the EAU #thromboprophylaxis guideline go?” Don’t worry. Check out cluevte.org 🚀 ✅ Not just #urology, also #gynecology & abd #surgery ✅ Procedure-specific VTE & bleeding risks ✅ Free interactive tool + static infographics #EBM